Novus Biologicals products are now on

TRAILR1/TNFRSF10A Antibody [Unconjugated]


Western blot shows lysates of TF‑1 human erythroleukemic cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) followed more
In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (Catalog # more
TRAIL R1/TNFRSF10A was detected in immersion fixed paraffin-embedded sections of human brain using Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) at 10 µg/mL more
B3GNT2 disrupts ligand–receptor interactions between tumor and T cells.a Cell survival against T cell cytotoxicity (top) and T cell IFN gamma secretion (bottom) in A375 cells overexpressing B3GNT2 or GFP that have more

Product Details

Reactivity HuSpecies Glossary
Applications WB, IHC, B/N

Order Details

View Available Conjugates
Catalog# & Conjugate Size Price
View Available Formulations
Catalog# & Formulation Size Price

TRAILR1/TNFRSF10A Antibody [Unconjugated] Summary

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A
Accession # AAC51226
Detects human TRAIL R1/TNFRSF10A in direct ELISAs and Western blots. In Western blots, approximately 10% cross-reactivity with recombinant human (rh) TRAIL R2 is observed and less than 1% cross-reactivity with rhTRAIL R3 and rhTRAIL R4 is observed.
Purity Statement
Antigen Affinity-purified
Endotoxin Note
<0.10 EU per 1 μg of the antibody by the LAL method.
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.


  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.02-0.055 ug/mL
  • Western Blot 1 ug/mL
Read Publications using
AF347 in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
No Preservative
Reconstitution Instructions
Reconstitute at 0.2 mg/mL in sterile PBS.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRAILR1/TNFRSF10A Antibody [Unconjugated]

  • APO2
  • CD261 antigen
  • CD261
  • cytotoxic TRAIL receptor
  • Death receptor 4
  • DR4 TRAIL receptor 1
  • DR4
  • TNF-related apoptosis inducing ligand receptor 1
  • TNF-related apoptosis-inducing ligand receptor 1
  • TRAIL R1
  • TRAIL-R1
  • TRAILR-1
  • TRAILR1MGC9365
  • tumor necrosis factor receptor superfamily member 10A
  • tumor necrosis factor receptor superfamily, member 10a


Human TRAIL R1, also called DR4, is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL RI is referred to as TNFRSF10A. TRAIL R1 cDNA encodes a 468 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among the TNF receptor family proteins, TRAIL R1 is most closely related to TRAIL R2/DR5, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R1 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R1/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R1, an additional TRAIL R2/DR5, which tranduces apoptosis signal, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

  1. Pan, G. et al. (1997) Science 276:111.
  2. Golstein, P. (1997) Curr. Biol. 7:R750.


This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: BA
Species: Hu, Mu
Applications: Flow-CS, Flow, ICC/IF, IHC, IHC-P, WB
Species: Ma, Hu, Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Simple Western, WB
Species: Hu
Applications: Bind
Species: Hu
Applications: IHC, Neut, WB
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu, Mu
Applications: WB
Species: Hu, Pm, Mu(-)
Applications: Flow, ICC/IF, IF, IHC, IHC-P, WB
Species: Hu
Applications: ICC/IF, IHC, IHC-P, WB
Species: Pm, Ca, Pm, Hu, Pm, Sq
Applications: Flow, ICC/IF
Species: Hu
Applications: ELISA, AP, PA, WB
Species: Ca, Hu, Mu, Rt
Applications: IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu
Applications: IHC, IHC-P, WB
Species: Hu
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
Species: Ca, Ma, Hu, Mu, Rt
Applications: Flow-IC, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Ca, Hu, Mu, Rt
Applications: IHC, IHC-P, IP, WB

Publications for TRAILR1/TNFRSF10A Antibody (AF347)(38)

We have publications tested in 1 confirmed species: Human.

We have publications tested in 8 applications: Bioassay, Flow Cytometry, ICC, IHC-Fr, IHC-P, Immunoprecipitation, Neutralization, Western Blot.

Filter By Application
Flow Cytometry
Western Blot
All Applications
Filter By Species
All Species
Showing Publications 1 - 10 of 38. Show All 38 Publications.
Publications using AF347 Applications Species
R Yerbes, R Mora-Molin, FJ Fernández-, L Hiraldo, A López-Riva, C Palacios Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cells Cell Death & Disease, 2022-10-27;13(10):906. 2022-10-27 [PMID: 36302756] (Western Blot, Human) Western Blot Human
J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity Nature Communications, 2022-03-25;13(1):1606. 2022-03-25 [PMID: 35338135] (Western Blot, Human) Western Blot Human
M Kopczynski, M Statkiewic, M Cybulska, U Kuklinska, K Unrug-Biel, Z Sandowska-, A Grochowska, M Gajewska, M Kulecka, J Ostrowski, M Mikula Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models International Journal of Molecular Sciences, 2021-03-19;22(6):. 2021-03-19 [PMID: 33808900] (ICC, Human) ICC Human
JD Yoo, SM Bae, J Seo, IS Jeon, SMP Vadevoo, SY Kim, IS Kim, B Lee, S Kim Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy Sci Rep, 2020-11-17;10(1):19997. 2020-11-17 [PMID: 33203916] (Bioassay, Human) Bioassay Human
Reema Baskar, Harris G Fienberg, Zumana Khair, Patricia Favaro, Sam Kimmey, Douglas R Green et al. TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis Life Science Alliance 12/1/2019 [PMID: 31704709]
S Serrano-Sa, C Palacios, D Delgado-Be, L López-Jimé, A Garcia-Dia, Y Soto-Serra, JI Casal, RA Bartolomé, JL Fernández-, A López-Riva, FJ Oliver PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism Cell Death Dis, 2019-01-18;10(2):51. 2019-01-18 [PMID: 30718520] (Western Blot, Human) Western Blot Human
Y Shlyakhtin, V Pavet, H Gronemeyer Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells Cell Death Dis, 2017-08-31;8(8):e3025. 2017-08-31 [PMID: 29048428] (Immunoprecipitation, Human) Immunoprecipitation Human
V Liapis, A Zysk, M DeNichilo, I Zinonos, S Hay, V Panagopoul, A Shoubridge, C Difelice, V Ponomarev, W Ingman, GJ Atkins, DM Findlay, ACW Zannettino, A Evdokiou Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma Cancer Med, 2017-08-10;0(0):. 2017-08-10 [PMID: 28799237] (Western Blot, Human) Western Blot Human
C Liang, Y Xu, G Li, T Zhao, F Xia, G Li, D Zhang, J Wu Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis Onco Targets Ther, 2017-01-18;10(0):417-428. 2017-01-18 [PMID: 28176915] (Neutralization, Human) Neutralization Human
Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins G, Findlay D, Zannettino A, Evdokiou A Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). Anticancer Res, 2014-12-01;34(12):7007-20. 2014-12-01 [PMID: 25503127] (Flow Cytometry, Human) Flow Cytometry Human
Show All 38 Publications.

Reviews for TRAILR1/TNFRSF10A Antibody (AF347) (0)

There are no reviews for TRAILR1/TNFRSF10A Antibody (AF347). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

Product General Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

Video Protocols

WB Video Protocol

FAQs for TRAILR1/TNFRSF10A Antibody (AF347) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.
mFluor Violet Conjugated Antibodies

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our TRAILR1/TNFRSF10A Antibody [Unconjugated] and receive a gift card or discount.


Gene Symbol TNFRSF10A